Bristol Myers Squibb Co (BMY) Files Form 4 Insider Selling : John E Elicker Sells 11,820 Shares

Bristol Myers Squibb Co (BMY): John E Elicker , SVP, Public Affairs & IR of Bristol Myers Squibb Co sold 11,820 shares on Jun 14, 2016. The Insider selling transaction was reported by the company on Jun 16, 2016 to the Securities and Exchange Commission. The shares were sold at $72.69 per share for a total value of $859,219.44 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 24, 2016, Charles A Bancroft (EVP & Chief Financial Officer) sold 30,201 shares at $70.79 per share price.On May 17, 2016, Joseph C Caldarella (SVP & Controller) sold 3,519 shares at $72.46 per share price.Also, On May 10, 2016, Sandra Leung (EVP, General Counsel) sold 72,544 shares at $70.39 per share price.On May 6, 2016, Lamberto Andreotti (director) sold 23,200 shares at $70.54 per share price.

Shares of Bristol-Myers Squibb Co (BMY) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.53 points or -0.73% at $72.57 with 53,90,075 shares getting traded. Post opening the session at $73.25, the shares hit an intraday low of $72.49 and an intraday high of $73.76 and the price vacillated in this range throughout the day. The company has a market cap of $121,142 M and the number of outstanding shares has been calculated to be 1,66,93,07,300 shares. The 52-week high of Bristol-Myers Squibb Co is $75.12 and the 52-week low is $51.82.

Bristol-Myers Squibb Co Money Flow Index Chart

On Jun 7, 2016, Bristol-Myers Squibb Co announced a cash dividend of $0.3800. The company’s management has announced Jun 29, 2016 as the ex-dividend date and fixed the record date on Jul 1, 2016. The payable date has been fixed on Aug 1, 2016.

Company has been under the radar of several Street Analysts.Bristol-Myers Squibb Co is Initiated by Hilliard Lyons to Neutral. The Rating was issued on May 23, 2016.Bristol-Myers Squibb Co is Reiterated by UBS to Buy and the brokerage firm has raised the Price Target to $ 80 from a previous price target of $73 .The Rating was issued on Apr 29, 2016.Bristol-Myers Squibb Co is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 75 from a previous price target of $70 .The Rating was issued on Apr 29, 2016.Bristol-Myers Squibb Co is Initiated by Societe Generale to Sell and the brokerage firm has set the Price Target at $48. The Rating was issued on Apr 6, 2016.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.